Literature DB >> 9091012

Use of oral misoprostol in the prevention of postpartum haemorrhage.

H el-Refaey1, P O'Brien, W Morafa, J Walder, C Rodeck.   

Abstract

OBJECTIVE: To investigate the use of the oral prostaglandin E1 analogue, misoprostol in the prevention of postpartum haemorrhage.
DESIGN: A prospective observational study.
SETTING: A university teaching hospital. PARTICIPANTS: Two hundred and thirty-seven consecutive women undergoing vaginal delivery.
METHODS: All the women were given 600 micrograms oral misoprostol just after delivery. MAIN OUTCOME MEASURES: Rates of postpartum haemorrhage; need for therapeutic oxytocic drugs; retained placenta and length of the third stage of labour.
RESULTS: Postpartum haemorrhage occurred in 6% of the women; the need for therapeutic oxytocics in 5%, retained placenta in 2% and the median length of the third stage was 5 min. Vomiting and diarrhoea in the first hour after delivery occurred in 8% and 3% respectively and shivering in 60%.
CONCLUSIONS: Misoprostol may be effective in the prevention of postpartum haemorrhage, and has few side effects. A double blind randomised trial is required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9091012     DOI: 10.1111/j.1471-0528.1997.tb11464.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  12 in total

Review 1.  Prostaglandins for preventing postpartum haemorrhage.

Authors:  Özge Tunçalp; G Justus Hofmeyr; A Metin Gülmezoglu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

2.  Different Doses of Sublingual Misoprostol versus Methylergometrine for the Prevention of Atonic Postpartum Haemorrhage.

Authors:  M H Soltan; E El-Gendi; H H Imam; O Fathi
Journal:  Int J Health Sci (Qassim)       Date:  2007-07

3.  High fever following postpartum administration of sublingual misoprostol.

Authors:  J Durocher; J Bynum; W León; G Barrera; B Winikoff
Journal:  BJOG       Date:  2010-04-19       Impact factor: 6.531

Review 4.  Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology.

Authors:  A N de Groot; P W van Dongen; T B Vree; Y A Hekster; J van Roosmalen
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

5.  Uses of misoprostol in obstetrics and gynecology.

Authors:  Rebecca Allen; Barbara M O'Brien
Journal:  Rev Obstet Gynecol       Date:  2009

Review 6.  Emerging targets in lipid-based therapy.

Authors:  Stephanie C Tucker; Kenneth V Honn
Journal:  Biochem Pharmacol       Date:  2012-12-20       Impact factor: 5.858

7.  The development of oxytocic drugs in the management of postpartum haemorrhage.

Authors:  Thomas F Baskett
Journal:  Ulster Med J       Date:  2004-05

8.  Osur et al.'s Implementation of misoprostol for postabortion care in Kenya and Uganda: a qualitative evaluation.

Authors:  Molly Moran; Joanna Ortega; Nuriye Nalan-Sahin Hodoglugil
Journal:  Glob Health Action       Date:  2012-07-18       Impact factor: 2.640

9.  The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial.

Authors:  Gilda Piaggio; Diana Elbourne; Kenneth F Schulz; José Villar; Alain P Y Pinol; A Metin Gülmezoglu
Journal:  BMC Med Res Methodol       Date:  2003-10-03       Impact factor: 4.615

10.  Advance distribution of misoprostol for prevention of postpartum hemorrhage (PPH) at home births in two districts of Liberia.

Authors:  Jeffrey Michael Smith; Saye Dahn Baawo; Marion Subah; Varwo Sirtor-Gbassie; Cuallau Jabbeh Howe; Gbenga Ishola; Bentoe Z Tehoungue; Vikas Dwivedi
Journal:  BMC Pregnancy Childbirth       Date:  2014-06-04       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.